IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Operating Income: ₹1,886 Mil (TTM As of Mar. 2026)

What is IOL Chemicals And Pharmaceuticals Operating Income?

IOL Chemicals And Pharmaceuticals NSE:IOLCP +2.11% 63 Operating Income is ₹1,886 Mil as of Mar. 2026. GuruFocus rates NSE:IOLCP with a GF Score™ of 63/100 and a GF Value™ of ₹93.94 (Significantly Overvalued). The stock has 7 warning signs investors should review.

IOL Chemicals And Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was ₹722 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,886 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. IOL Chemicals And Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was ₹722 Mil. IOL Chemicals And Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was ₹6,195 Mil. Therefore, IOL Chemicals And Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 was 11.65%.

Warning Sign:

IOL Chemicals And Pharmaceuticals Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -19.7%.

IOL Chemicals And Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was -19.70% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IOL Chemicals And Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was 11.45%. IOL Chemicals And Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 17.18%.

IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IOL Chemicals And Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	2887.2 * ( 1 - 24.93% )	/	( (0	+	18927.2)	/ 1 )
=	2167.42104	/	18927.2
=	11.45 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25869.5	-	4849.1	-	( 2093.2	-	max(0, 6901.8	-	12276.3	+	2093.2	))
=	18927.2

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

IOL Chemicals And Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2960.4	/	( ( (0 + max(0, 0))	+	(12624 + max(4611.5, 0)) )	/	1 )
=	2960.4	/	( ( 0	+	17235.5 )	/	1 )
=	2960.4	/	17235.5
=	17.18 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6031.3	+	3710.7	+	441.1)	-	(4849.1	+	0	+	722.5)
=	4611.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

IOL Chemicals And Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	721.8	/	6194.5
	=	11.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

IOL Chemicals And Pharmaceuticals Operating Income Related Terms

IOL Chemicals And Pharmaceuticals Operating Income Historical Data

* Premium members only.

The historical data trend for IOL Chemicals And Pharmaceuticals's Operating Income can be seen below:

IOL Chemicals And Pharmaceuticals Operating Income Chart

IOL Chemicals And Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Operating Income

Get a 7-Day Free Trial

2,161.90

1,801.70

1,679.30

1,303.10

1,887.60

IOL Chemicals And Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Operating Income	Get a 7-Day Free Trial															442.00	422.70	370.90	371.00	721.80

63GF Score

IOL Chemicals And Pharmaceuticals Ltd NSE:IOLCP

Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

IOL Chemicals And Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,886 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of ₹1,886 Mil mean?

IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a Operating Income of ₹1,886 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on IOL Chemicals And Pharmaceuticals and its competitors.

Is IOL Chemicals And Pharmaceuticals' Operating Income too high?

IOL Chemicals And Pharmaceuticals' current Operating Income is ₹1,886 Mil. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does IOL Chemicals And Pharmaceuticals' Operating Income compare to ZTS and UTHR?

IOL Chemicals And Pharmaceuticals' Operating Income of ₹1,886 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Drug Manufacturers company?

A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. IOL Chemicals And Pharmaceuticals's current Operating Income is ₹1,886 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is IOL Chemicals And Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹93.94, compared to a current price of ₹150.31 — trading 60% above its estimated fair value. The current Operating Income is ₹1,886 Mil. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current Operating Income is ₹1,886 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?

Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued. The current stock price of ₹150.31 is trading 60% above its estimated GF Value™ of ₹93.94. GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:IOLCP:

Operating Income: ₹1,886 Mil
GF Value™: ₹93.94 vs. price of ₹150.31 (60% above fair value)
GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IOL Chemicals And Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NSE:RPGLIFE BOM:509079 BOM:506879 BOM:500672 BOM:524348 BOM:506690 BOM:524372 BOM:500288 BOM:541540 BOM:524735 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 524164:India

Address 85, Industrial Area, A, Ludhiana, PB, IND, 141 003

Website https://www.iolcp.com

IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.

63GF Score

Get the complete analysis for NSE:IOLCP

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹150.31

Price

₹93.94

GF Value

View NSE:IOLCP Analysis

See Operating Income data for all stocks →